A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Life expectancy of at least 12 weeks

- Adequate hematologic and end organ function

- Histologic documentation of locally advanced, recurrent, or metastatic incurable solid
malignancy that has progressed after available standard therapy; or for which standard
therapy is ineffective, intolerable, or considered inappropriate; or for which a
clinical trial of an investigational agent is recognized standard of care

- Tumor specimen availability

- Measurable disease according to RECIST v1.1

Exclusion Criteria:

- Any anti-cancer therapy, whether investigational or approved, including chemotherapy,
hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study
treatment

- Malignancies other than disease under study within 5 years prior to D1 of C1

- Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases

- History of leptomeningeal disease

- History of idiopathic pulmonary fibrosis, pneumonitis (including drug-induced),
organizing pneumonia, or evidence of active pneumonitis on screening chest computed
tomography scan; history of radiation pneumonitis in the radiation field (fibrosis) is
permitted

- History of autoimmune disease

- Positive human immunodeficiency virus test result

- Active hepatitis B, hepatitis C, or tuberculosis

- Severe infection within 4 weeks prior to D1 of C1

- Prior allogeneic bone marrow or solid organ transplantation

- Significant cardiovascular disease

- Known clinically significant liver disease